World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
132
Citations
84570
World Ranking
2278
National Ranking
1286

Overview

Nicholas J. Vogelzang is affiliated with the University of Nevada Reno in the United States and has contributed extensively to the field of medicine, specifically within oncology and pulmonary and respiratory medicine. Their research output includes significant work in related subfields such as surgery, radiology, nuclear medicine and imaging, and cancer research.

Their scientific contributions focus on key topics including:

  • Prostate Cancer Treatment and Research
  • Cancer Immunotherapy and Biomarkers
  • Radiopharmaceutical Chemistry and Applications
  • Bladder and Urothelial Cancer Treatments
  • Cancer Genomics and Diagnostics
  • Renal Cell Carcinoma Treatment
  • PARP Inhibition in Cancer Therapy

They have collaborated frequently with several researchers, including:

  • Maha Hussain
  • David I. Quinn
  • Celestia S. Higano
  • Ian M. Thompson
  • Petros Grivas

Major venues for their publications include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Clinical Genitourinary Cancer
  • Clinical Cancer Research
  • The Lancet Oncology

Selected recent publications are as follows:

  • Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial, 2020, The Lancet
  • Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration, 2020, Journal of Clinical Oncology
  • Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study, 2020, Clinical Cancer Research
  • Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma, 2023, Journal of Clinical Oncology
  • Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study, 2021, The Lancet Oncology

Their publication record spans over 265 works primarily in medicine, with a pronounced focus on oncology-related disciplines.

Best Publications

  • Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

    C. Parker;S. Nilsson;S. Nilsson;D. Heinrich;S. I. Helle

  • Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

    Nicholas J. Vogelzang;James J. Rusthoven;James Symanowski;Claude Denham

  • Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

    Joaquim Bellmunt;Ronald De Wit;David J. Vaughn;Yves Fradet

  • Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

    Christopher J. Sweeney;Yu Hui Chen;Michael Carducci;Glenn Liu

  • Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer

    H. Barton Grossman;Ronald B. Natale;Catherine M. Tangen;V.O. Speights

  • MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

    Thomas Powles;Joseph Paul Eder;Gregg D. Fine;Fadi S. Braiteh

  • Impact of Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition

    Gregory A. Curt;William Breitbart;David Cella;Jerome E. Groopman

  • Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

    Thomas Powles;Ignacio Durán;Michiel S van der Heijden;Yohann Loriot

  • Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

    Karim Fizazi;Howard I. Scher;Arturo Molina;Christopher J. Logothetis

  • Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study

    Philip W. Kantoff;Susan Halabi;Mark Conaway;Joel Picus

  • Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ Production

    John P. Leonard;Matthew L. Sherman;Gerald L. Fisher;Lynn J. Buchanan

  • Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

    Christos E. Kyriakopoulos;Yu Hui Chen;Michael A. Carducci;Glenn Liu

  • Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

    Jyoti D. Patel;Lada Krilov;Sylvia Adams;Carol Aghajanian

  • Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study

    Thomas Powles;Peter H. O'Donnell;Christophe Massard;Hendrik Tobias Arkenau

  • Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer

    Susan Halabi;Eric J. Small;Philip W. Kantoff;Michael W. Kattan

  • Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline

    D. Andrew Loblaw;Katherine S. Virgo;Robert Nam;Mark R. Somerfield

  • Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

    Eric J. Small;Susan Halabi;Nancy A. Dawson;Walter M. Stadler

  • Factors Predictive of Survival Among 337 Patients With Mesothelioma Treated Between 1984 and 1994 by the Cancer and Leukemia Group B

    James E. Herndon;Mark R. Green;A. Phillippe Chahinian;Joseph M. Corson

  • Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.

    Matthew D. Galsky;José Ángel Arranz Arija;Aristotelis Bamias;Ian D. Davis

  • Intermittent versus continuous androgen deprivation in prostate cancer.

    Maha Hussain;Catherine M. Tangen;Donna L. Berry;Celestia S. Higano

Frequent Co-Authors

David I. Quinn
David I. Quinn University of Southern California
Maha Hussain
Maha Hussain Northwestern University
Ian M. Thompson
Ian M. Thompson The University of Texas Health Science Center at San Antonio
Celestia S. Higano
Celestia S. Higano University of Washington
Mark J. Ratain
Mark J. Ratain University of Chicago
Neal D. Shore
Neal D. Shore Carolina Urologic Research Center
Catherine M. Tangen
Catherine M. Tangen Fred Hutchinson Cancer Research Center
Chris Parker
Chris Parker Institute of Cancer Research
Walter M. Stadler
Walter M. Stadler University of Chicago
Joaquim Bellmunt
Joaquim Bellmunt Beth Israel Deaconess Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring the medical field isn't limited to pursuing a traditional M.D. There are flexible and affordable online alternatives for those interested in healthcare careers. Many nurses aim to advance professionally by completing one of the rn to bsn cheapest programs, which allow registered nurses to earn a bachelor’s degree quickly and affordably.

If you're considering a graduate-level path but do not yet have nursing experience, direct entry np programs for non nurses online can be a fast pathway to becoming a nurse practitioner without a prior nursing background.

For those starting out and seeking accessible entry points into nursing, there are easy nursing schools to get into that help make this career choice more attainable.

Not everyone interested in medicine works directly with patients; administrative roles are crucial too. Consider training through one of the medical billing and coding online schools to start a rewarding career in healthcare support.

Best Scientists Citing Nicholas J. Vogelzang

Trending Scientists

Recently Published Articles